Search clinical trials for: dexilansoprazole (Dexilant 60 mg)

Total 366 results

American University of Beirut Medical Center
Takeda

Completed

An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan

GERD | Proton Pump Inhibitor

Lebanon
Taipei Veterans General Hospital, Taiwan

Unknown

Comparison of the Efficiency of Two Different PPI Formula in Atypical GERD

Compare the Response Rate of Atypical GERD After PPI Therapy

Taiwan
University of Karachi
SAMI Pharmaceutical, Karachi Pakistan

Completed

Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects. (BABE)

Healthy | Bioequivalence Study

Pakistan
Ramathibodi Hospital

Completed

Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori

H Pylori Eradication

Thailand
Takeda

Completed

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

Healthy Volunteers

United States
Takeda

Completed

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

Healthy Volunteers

United States
University of Iowa

Withdrawn

Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain (Dexilant)

Chest Pain | Gastrointestinal Reflux Disease

United States
Kaohsiung Veterans General Hospital.

Completed

Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy

Helicobacter Pylori Infection

Taiwan
Takeda

Terminated

Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation

Barrett's Esophagus

United States
Northwestern University
Washington University School of Medicine; Vanderbilt University

Completed

Effectiveness of Physiologic Testing in PPI Non-Responders

Gastro Esophageal Reflux

United States
Mayo Clinic

Withdrawn

Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis

Gastroesophageal Reflux Disease | Dysphagia | Eosinophilic Esophagitis
Takeda

Completed

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Takeda

Completed

Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease

Gastroesophageal Reflux

United States
Indiana University

Terminated

The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux

Laryngopharyngeal Reflux

United States
Mayo Clinic

Completed

Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

Inflammation | Barrett's Esophagus

United States
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Poland, Bulgaria, India, South Africa, Canada, Peru, New Zealand, Australia, Lithuania, Slovakia, Hungary, Latvia, Germany, Czech Republic
Takeda

Completed

Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants

Bioavailability

United States
Vifor (International) Inc.
Labcorp Drug Development Inc

Withdrawn

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Beta-Thalassemia

United States, Bulgaria, Israel
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Canada, Czech Republic, Lithuania, Slovakia, Latvia, Estonia, Australia
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States
Grünenthal GmbH

Completed

A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it

Pain | Chronic Pain | Neuropathic Pain | Visceral Pain

Germany
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

United States
Advanced Center for Specialty Care
Takeda

Unknown

Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy

Laryngopharyngeal Reflux | Hypertrophy of Lingual Tonsil

United States
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B

Gastroesophageal Reflux Disease
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Poland, Bulgaria, India, Canada, Peru, Russian Federation, Australia, New Zealand, Czech Republic, Slovakia, South Africa, Latvia, Lithuania, Colombia, Germany
Takeda

Completed

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

Gastroesophageal Reflux Disease

United States, Poland, Belgium, Portugal, Italy, Hungary, Mexico, Brazil
Sobi, Inc.

Terminated

Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

Thrombocytopenia

United States
Suzhou Kintor Pharmaceutical Inc,

Completed

Phase II Study Evaluating the Efficacy and Safety of KX-826

Androgenetic Alopecia (AGA)

China
University of Florence
Azienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaborators

Recruiting

Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients (STAR)

Migraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura

Italy
AbbVie

Active, not recruiting

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

Chronic Migraine | Episodic Migraine

United States, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, United Kingdom
AbbVie

Active, not recruiting

A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

Chronic Migraine | Episodic Migraine

Japan
H. Lundbeck A/S

Completed

Bioequivalence Study of Idalopirdine Tablets 60 mg

Healthy

United Kingdom
Takeda

Recruiting

A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children

Erosive Esophagitis

United States, Lithuania, Mexico, Canada, Colombia, Poland
Takeda

Recruiting

A Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children

Gastroesophageal Reflux Disease (GERD)

United States, Lithuania, Mexico, Canada, Colombia, Poland
University of Washington
Takeda Pharmaceuticals North America, Inc.

Withdrawn

Evaluating Treatment Response in Laryngo-Pharyngeal Reflux

Laryngo-pharyngeal Reflux

United States
Takeda

Completed

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Gastroesophageal Reflux

United States
GlaxoSmithKline

Completed

Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid

Spain, Germany, Russian Federation, United Kingdom, Italy, Poland
Allergan

Completed

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. (ELEVATE)

Episodic Migraine

United States, Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, United Kingdom
Genuine Research Center, Egypt
Hikma Pharma,Egypt

Completed

A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)

Healthy

Egypt
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents

Gastroesophageal Reflux Disease | Erosive Esophagitis

United States, Poland, Belgium, Portugal, Italy, Hungary, Mexico, Brazil
Hoffmann-La Roche

Recruiting

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Huntington Disease

United States, Australia, Argentina, Canada, Germany, Italy, Spain, France, United Kingdom, Portugal, New Zealand, Austria, Poland, Switzerland, Denmark
PHARMENTERPRISES LLC

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

Influenza | Acute Respiratory Infection

Russian Federation
Allergan

Completed

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Chronic Migraine

United States, Australia, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Sweden, Taiwan, United Kingdom
Takeda

Completed

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States
HK inno.N Corporation

Completed

Pharmacodynamic Properties of CJ-12420 on Evening Dosing

Healthy

Korea, Republic of
University of Bologna
Ipsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaborators

Unknown

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

Non Small Cell Lung Cancer

Italy
H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function

Alzheimer Disease

Germany
Takeda

Completed

Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease

Gastroesophageal Reflux

United States

Search clinical trials for: dexilansoprazole (Dexilant 60 mg)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations